Cover Image
Market Research Report

Gram-positive Bacterial Infections Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Published by Transparency Market Research Product code 799162
Published Content info 225 Pages
Delivery time: 1-2 business days
Price
Back to Top
Gram-positive Bacterial Infections Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026
Published: February 5, 2019 Content info: 225 Pages
Description

Title:
Gram-positive Bacterial Infections Market (Drug Type - Antibiotic (B-Lactam, Quinolones, Macrolides, Tetracyclines, Aminoglycosides, Sulfonamides, Phenicols), Antifungal; Disease - MRSA, Pneumonia, Sepsis, Sinusitis, Cellulitis, Otitis, Pharyngitis, Impetigo; Route of Administration - Enteral, Parenteral; Distribution Channel - Hospital Pharmacies, Drug Stores and Retail Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026.

Gram-positive Bacterial Infections Market - Overview

Bacterial infections are a major cause of illness and are generally acquired through various sources. Based on staining, bacteria are classified into two types: gram-positive and gram-negative. Gram-positive bacteria retain gram stain and hence, are observed as violet purple colored stains when observed under the microscope. They are a major class of bacteria and cause various infections in humans. Gram-positive bacterial infections drugs act against gram-positive bacterial infections such as MRSA infections, sinusitis, cellulitis, and pneumonia. Antibiotics are widely used as the first line of treatment for these infections. Antibacterial resistance is considered to be a serious threat in this century for the treatment of bacterial infections. The market for gram-positive bacterial infections is expanding significantly due to a rise in the number of cases of bacterial infections and rapid increase in antibacterial resistance. Furthermore, infection control in healthcare settings and increasing government initiatives & funding for R&D activities have fuelled the gram-positive bacterial infections market.

The gram-positive bacterial infections market has been exclusively analyzed based on drug type, disease, route of administration, distribution channel, and region. Based on drug type, the global market has been divided into antibiotic, antifungal and others. The antibiotic segment has been further sub-segmented into B-Lactam, quinolones, macrolides, tetracyclines, aminoglycosides, sulfonamides, phenicols, and others. In terms of disease, the global gram-positive bacterial infections market has been segmented into MRSA, pneumonia, sepsis, sinusitis, cellulitis, otitis, pharyngitis, impetigo, and others. Based on route of administration, the global market has been classified into enteral, parenteral, and others. Based on distribution channel, the global gram-positive bacterial infections market has been split into hospital pharmacies, drug stores and retail pharmacies, and others. Each of the segments has been analyzed in detail for market trends, recent trends and developments, drivers, restraints, opportunities and useful insights. The report gives current and future market size for each segment and sub segments for the period from 2018 to 2026 in terms of revenue in US$ Mn, considering 2017 as the base year. The compound annual growth rate (%CAGR) has been provided for each segment and market for the period of 2018 to 2026 with market size estimations.

In terms of region, the global market has been segregated into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been further sub-segmented into major countries and sub-regions. The current and future market sizes in terms of revenue (US$ Mn) of these regional markets and their major countries have been provided in the report for the period from 2016 to 2026, with their growth rate (%) for the period from 2018 to 2026. The study also offers a list of recommendations, highlights and some useful insights of the market which will surely help new companies willing to enter the market and for existing companies to increase market shares, which is likely to help in the decision-making process.

The market overview section of the report demonstrates the market dynamics and market trends such as drivers, restraints and opportunities that influence the current and future status of the gram-positive bacterial infections market. The report also covers market revenue projections, market attractiveness analysis and key market share analysis in the market overview section in order to provide a thorough analysis of the overall competitive scenario in the global gram-positive bacterial infections market.

The report concludes with the company profiles section that includes key information about the major players in the market. Key players identified in this report are Bayer AG, Pfizer, Inc., Sanofi, GlaxoSmithkline plc (GSK), Merck & Co., Inc., AstraZeneca, Theravance Biopharma, Bristol-Myers Squibb Company, Novartis AG, and Allergan plc. Each of these players has been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, Business segments and recent developments.

The global gram-positive bacterial infections market has been segmented as follows:

Global Gram-positive Bacterial Infections Market, by Drug Type

  • Antibiotic
    • B-lactam
    • Quinolones
    • Macrolides
    • Tetracyclines
    • Aminoglycosides
    • Sulfonamides
    • Phenicols
    • Others
  • Antifungal
  • Others (Antitoxins, Corticosteroids, Supplements, Anti-Dialectic)

Global Gram-positive Bacterial Infections Market, by Disease

  • MRSA
  • Pneumonia
  • Sepsis
  • Sinusitis
  • Cellulitis
  • Otitis
  • Pharyngitis
  • Impetigo
  • Others (Anthrax, Erysipelothricosis, Necrotizing Fasciitis, Scarlet Fever, and Listeria)

Global Gram-positive Bacterial Infections Market, by Route of Administration

  • Enteral
  • Parenteral
  • Others (Topical, Transdermal)

Global Gram-positive Bacterial Infections Market, by Distribution Channel

  • Hospitals Pharmacies
  • Drug Stores and Retail Pharmacies
  • Others (Online Pharmacies, Mail Pharmacies, and Home Care Pharmacies)

Global Gram-positive Bacterial Infections Market, by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of the Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa
Table of Contents

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Gram-positive Bacterial Infections Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Drug Type Definition
    • 4.1.2. Global Gram-positive Bacterial Infections Market Taxonomy
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Gram-positive Bacterial Infections Market Analysis and Forecast, 2016-2026
    • 4.4.1. Market Revenue Projections (US$ Mn)
  • 4.5. Porter's Five Force Analysis

5. Market Outlook

  • 5.1. Patent Landscape
  • 5.2. Key Success Factors of Top Players
  • 5.3. Branded vs. Generic Drugs Overview

6. Global Gram-positive Bacterial Infections Market Analysis and Forecast, by Drug Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Global Gram-positive Bacterial Infections Market Value Forecast, by Drug Type, 2016-2026
    • 6.3.1. Antibiotic
      • 6.3.1.1. B-Lactam
      • 6.3.1.2. Quinolones
      • 6.3.1.3. Macrolides
      • 6.3.1.4. Tetracyclines
      • 6.3.1.5. Aminoglycosides
      • 6.3.1.6. Sulfonamides
      • 6.3.1.7. Phenicols
      • 6.3.1.8. Others
    • 6.3.2. Antifungal
    • 6.3.3. Others
  • 6.4. Global Gram-positive Bacterial Infections Market Attractiveness, by Drug Type

7. Global Gram-positive Bacterial Infections Market Analysis and Forecast, by Disease

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Global Gram-positive Bacterial Infections Market Value Forecast, by Disease, 2016-2026
    • 7.3.1. MRSA
    • 7.3.2. Pneumonia
    • 7.3.3. Sepsis
    • 7.3.4. Sinusitis
    • 7.3.5. Cellulitis
    • 7.3.6. Otitis
    • 7.3.7. Pharyngitis
    • 7.3.8. Impetigo
    • 7.3.9. Others
  • 7.4. Global Gram-positive Bacterial Infections Market Attractiveness, by Drug Type

8. Global Gram-positive Bacterial Infections Market Analysis and Forecast, by Route of Administration

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Global Gram-positive Bacterial Infections Market Value Forecast, by Route of Administration, 2016-2026
    • 8.3.1. Enteral
    • 8.3.2. Parenteral
    • 8.3.3. Others
  • 8.4. Global Gram-positive Bacterial Infections Market Attractiveness, by Route of Administration

9. Global Gram-positive Bacterial Infections Market Analysis and Forecast, by Distribution Channel

  • 9.1. Introduction & Definition
  • 9.2. Key Findings / Developments
  • 9.3. Global Gram-positive Bacterial Infections Market Value Forecast, by Distribution Channel, 2016-2026
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Drug Stores and Retail Pharmacies
    • 9.3.3. Others
  • 9.4. Global Gram-positive Bacterial Infections Market Attractiveness, by Distribution Channel

10. Global Gram-positive Bacterial Infections Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Global Gram-positive Bacterial Infections Market Value Forecast, by Region
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Global Gram-positive Bacterial Infections Market Attractiveness, by Region

11. North America Gram-positive Bacterial Infections Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. North America Gram-positive Bacterial Infections Market Value Forecast, by Drug Type, 2016-2026
    • 11.2.1. Antibiotic
      • 11.2.1.1. B-Lactam
      • 11.2.1.2. Quinolones
      • 11.2.1.3. Macrolides
      • 11.2.1.4. Tetracyclines
      • 11.2.1.5. Aminoglycosides
      • 11.2.1.6. Sulfonamides
      • 11.2.1.7. Phenicols
      • 11.2.1.8. Others
    • 11.2.2. Antifungal
    • 11.2.3. Others
  • 11.3. North America Gram-positive Bacterial Infections Market Value Forecast, by Disease, 2016-2026
    • 11.3.1. MRSA
    • 11.3.2. Pneumonia
    • 11.3.3. Sepsis
    • 11.3.4. Sinusitis
    • 11.3.5. Cellulitis
    • 11.3.6. Otitis
    • 11.3.7. Pharyngitis
    • 11.3.8. Impetigo
    • 11.3.9. Others
  • 11.4. North America Gram-positive Bacterial Infections Market Value Forecast, by Route of Administration, 2016-2026
    • 11.4.1. Enteral
    • 11.4.2. Parenteral
    • 11.4.3. Others
  • 11.5. North America Gram-positive Bacterial Infections Market Value Forecast, by Distribution Channel, 2016-2026
    • 11.5.1. Hospital Pharmacies
    • 11.5.2. Drug Stores and Retail Pharmacies
    • 11.5.3. Others
  • 11.6. North America Gram-positive Bacterial Infections Market Value Forecast, by Country, 2016-2026
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. North America Gram-positive Bacterial Infections Market Attractiveness Analysis
    • 11.7.1. By Drug Type
    • 11.7.2. By Disease
    • 11.7.3. By Route of Administration
    • 11.7.4. By Distribution Channel
    • 11.7.5. By Country

12. Europe Gram-positive Bacterial Infections Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Europe Gram-positive Bacterial Infections Market Value Forecast, by Drug Type, 2016-2026
    • 12.2.1. Antibiotic
      • 12.2.1.1. B-Lactam
      • 12.2.1.2. Quinolones
      • 12.2.1.3. Macrolides
      • 12.2.1.4. Tetracyclines
      • 12.2.1.5. Aminoglycosides
      • 12.2.1.6. Sulfonamides
      • 12.2.1.7. Phenicols
      • 12.2.1.8. Others
    • 12.2.2. Antifungal
    • 12.2.3. Others
  • 12.3. Europe Gram-positive Bacterial Infections Market Value Forecast, by Disease, 2016-2026
    • 12.3.1. MRSA
    • 12.3.2. Pneumonia
    • 12.3.3. Sepsis
    • 12.3.4. Sinusitis
    • 12.3.5. Cellulitis
    • 12.3.6. Otitis
    • 12.3.7. Pharyngitis
    • 12.3.8. Impetigo
    • 12.3.9. Others
  • 12.4. Europe Gram-positive Bacterial Infections Market Value Forecast, by Route of Administration, 2016-2026
    • 12.4.1. Enteral
    • 12.4.2. Parenteral
    • 12.4.3. Others
  • 12.5. Europe Gram-positive Bacterial Infections Market Value Forecast, by Distribution Channel, 2016-2026
    • 12.5.1. Hospital Pharmacies
    • 12.5.2. Drug Stores and Retail Pharmacies
    • 12.5.3. Others
  • 12.6. Europe Gram-positive Bacterial Infections Market Value Forecast, by Country/Sub-region, 2016-2026
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
    • 12.6.4. Italy
    • 12.6.5. Spain
    • 12.6.6. Rest of Europe
  • 12.7. Europe Gram-positive Bacterial Infections Market Attractiveness Analysis
    • 12.7.1. By Drug Type
    • 12.7.2. By Disease
    • 12.7.3. By Route of Administration
    • 12.7.4. By Distribution Channel
    • 12.7.5. By Country/Sub-region

13. Asia Pacific Gram-positive Bacterial Infections Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Asia Pacific Gram-positive Bacterial Infections Market Value Forecast, by Drug Type, 2016-2026
    • 13.2.1. Antibiotic
      • 13.2.1.1. B-Lactam
      • 13.2.1.2. Quinolones
      • 13.2.1.3. Macrolides
      • 13.2.1.4. Tetracyclines
      • 13.2.1.5. Aminoglycosides
      • 13.2.1.6. Sulfonamides
      • 13.2.1.7. Phenicols
      • 13.2.1.8. Others
    • 13.2.2. Antifungal
    • 13.2.3. Others
  • 13.3. Asia Pacific Gram-positive Bacterial Infections Market Value Forecast, by Disease, 2016-2026
    • 13.3.1. MRSA
    • 13.3.2. Pneumonia
    • 13.3.3. Sepsis
    • 13.3.4. Sinusitis
    • 13.3.5. Cellulitis
    • 13.3.6. Otitis
    • 13.3.7. Pharyngitis
    • 13.3.8. Impetigo
    • 13.3.9. Others
  • 13.4. Asia Pacific Gram-positive Bacterial Infections Market Value Forecast, by Route of Administration, 2016-2026
    • 13.4.1. Enteral
    • 13.4.2. Parenteral
    • 13.4.3. Others
  • 13.5. Asia Pacific Gram-positive Bacterial Infections Market Value Forecast, by Distribution Channel, 2016-2026
    • 13.5.1. Hospital Pharmacies
    • 13.5.2. Drug Stores and Retail Pharmacies
    • 13.5.3. Others
  • 13.6. Asia Pacific Gram-positive Bacterial Infections Market Value Forecast, by Country/Sub-region, 2016-2026
    • 13.6.1. China
    • 13.6.2. India
    • 13.6.3. Japan
    • 13.6.4. Australia & New Zealand
    • 13.6.5. Rest of APAC
  • 13.7. Asia Pacific Gram-positive Bacterial Infections Market Attractiveness Analysis
    • 13.7.1. By Drug Type
    • 13.7.2. By Disease
    • 13.7.3. By Route of Administration
    • 13.7.4. By Distribution Channel
    • 13.7.5. By Country/Sub-region

14. Latin America Gram-positive Bacterial Infections Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Latin America Gram-positive Bacterial Infections Market Value Forecast, by Drug Type,2016-2026
    • 14.2.1. Antibiotic
      • 14.2.1.1. B-Lactam
      • 14.2.1.2. Quinolones
      • 14.2.1.3. Macrolides
      • 14.2.1.4. Tetracyclines
      • 14.2.1.5. Aminoglycosides
      • 14.2.1.6. Sulfonamides
      • 14.2.1.7. Phenicols
      • 14.2.1.8. Others
    • 14.2.2. Antifungal
    • 14.2.3. Others
  • 14.3. Latin America Gram-positive Bacterial Infections Market Value Forecast, by Disease, 2016-2026
    • 14.3.1. MRSA
    • 14.3.2. Pneumonia
    • 14.3.3. Sepsis
    • 14.3.4. Sinusitis
    • 14.3.5. Cellulitis
    • 14.3.6. Otitis
    • 14.3.7. Pharyngitis
    • 14.3.8. Impetigo
    • 14.3.9. Others
  • 14.4. Latin America Gram-positive Bacterial Infections Market Value Forecast, by Route of Administration, 2016-2026
    • 14.4.1. Enteral
    • 14.4.2. Parenteral
    • 14.4.3. Others
  • 14.5. Latin America Gram-positive Bacterial Infections Market Value Forecast, by Distribution Channel, 2016-2026
    • 14.5.1. Hospital Pharmacies
    • 14.5.2. Drug Stores and Retail Pharmacies
    • 14.5.3. Others
  • 14.6. Latin America Gram-positive Bacterial Infections Market Value Forecast, by Country/Sub-region, 2016-2026
    • 14.6.1. Brazil
    • 14.6.2.Mexico
    • 14.6.3. Rest of LATAM
  • 14.7. Latin America Gram-positive Bacterial Infections Market Attractiveness Analysis
    • 14.7.1. By Drug Type
    • 14.7.2. By Disease
    • 14.7.3. By Route of Administration
    • 14.7.4. By Distribution Channel
    • 14.7.5. By Country/Sub-region

15. Middle East & Africa Gram-positive Bacterial Infections Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Middle East & Africa Gram-positive Bacterial Infections Market Value Forecast, by Drug Type, 2016-2026
    • 15.2.1. Antibiotic
      • 15.2.1.1. B-Lactam
      • 15.2.1.2. Quinolones
      • 15.2.1.3. Macrolides
      • 15.2.1.4. Tetracyclines
      • 15.2.1.5. Aminoglycosides
      • 15.2.1.6. Sulfonamides
      • 15.2.1.7. Phenicols
      • 15.2.1.8. Others
    • 15.2.2. Antifungal
    • 15.2.3. Others
  • 15.3. Middle East & Africa Gram-positive Bacterial Infections Market Value Forecast, by Disease, 2016-2026
    • 15.3.1. MRSA
    • 15.3.2. Pneumonia
    • 15.3.3. Sepsis
    • 15.3.4. Sinusitis
    • 15.3.5. Cellulitis
    • 15.3.6. Otitis
    • 15.3.7. Pharyngitis
    • 15.3.8. Impetigo
    • 15.3.9. Others
  • 15.4. Middle East & Africa Gram-positive Bacterial Infections Market Value Forecast, by Route of Administration, 2016-2026
    • 15.4.1. Enteral
    • 15.4.2. Parenteral
    • 15.4.3. Others
  • 15.5. Middle East & Africa Gram-positive Bacterial Infections Market Value Forecast, by Distribution Channel, 2016-2026
    • 15.5.1. Hospital Pharmacies
    • 15.5.2. Drug Stores and Retail Pharmacies
    • 15.5.3. Others
  • 15.6. Middle East & Africa Gram-positive Bacterial Infections Market Value Forecast, by Country/Sub-region, 2016-2026
    • 15.6.1. GCC Countries
    • 15.6.2.South Africa
    • 15.6.3. Rest of Middle East & Africa
  • 15.7. Market Attractiveness Analysis
    • 15.7.1. By Drug Type
    • 15.7.2. By Disease
    • 15.7.3. By Route of Administration
    • 15.7.4. By Distribution Channel
    • 15.7.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player-Competition Matrix(By Tier and Size of companies)
  • 16.2. Market Share Analysis By Tier and Size of the Company(2017)
  • 16.3. Company Profiles
    • 16.3.1. Bayer AG
    • 16.3.2. Pfizer, Inc.
    • 16.3.3. Sanofi
    • 16.3.4. GlaxoSmithKline plc
    • 16.3.5. Merck & Co., Inc.
    • 16.3.6. AstraZeneca
    • 16.3.7. Theravance Biopharma
    • 16.3.8. Bristol-Myers Squibb Company
    • 16.3.9. Novartis AG
    • 16.3.10. Allergan plc.

List of Tables

  • Table 01: Recent Patents, Gram-Positive Bacterial Infection Drugs
  • Table 02: Branded Drug Patents and Generic Drugs Overview
  • Table 03: Global Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Drug Type, 2016-2026
  • Table 04: Global Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Antibiotic, 2016-2026
  • Table 05: Global Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Disease, 2016-2026
  • Table 06: Global Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Route of Administration, 2016-2026
  • Table 07: Global Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 08: Global Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Region, 2016-2026
  • Table 09: North America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Country, 2016-2026
  • Table 10: North America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Drug Type, 2016-2026
  • Table 11: North America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Antibiotic, 2016-2026
  • Table 12: North America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Disease, 2016-2026
  • Table 13: North America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Route of Administration, 2016-2026
  • Table 14: North America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 15: Europe Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
  • Table 16: Europe Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Drug Type, 2016-2026
  • Table 17: Europe Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Antibiotic, 2016-2026
  • Table 18: Europe Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Disease, 2016-2026
  • Table 19: Europe Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Route of Administration, 2016-2026
  • Table 20: Europe Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 21: Asia Pacific Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
  • Table 22: Asia Pacific Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Drug Type, 2016-2026
  • Table 23: Asia Pacific Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Antibiotic, 2016-2026
  • Table 24: Asia Pacific Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Disease, 2016-2026
  • Table 25: Asia Pacific Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Route of Administration, 2016-2026
  • Table 26: Asia Pacific Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 27: Latin America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
  • Table 28: Latin America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Drug Type, 2016-2026
  • Table 29: Latin America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Antibiotic, 2016-2026
  • Table 30: Latin America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Disease, 2016-2026
  • Table 31: Latin America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Route of Administration, 2016-2026
  • Table 32: Latin America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 33: Middle East & Africa Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
  • Table 34: Middle East & Africa Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Drug Type, 2016-2026
  • Table 35: Middle East & Africa Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Antibiotic, 2016-2026
  • Table 36: Middle East & Africa Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Disease, 2016-2026
  • Table 37: Middle East & Africa Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Route of Administration, 2016-2026
  • Table 38: Middle East & Africa Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, by Distribution Channel, 2016-2026

List of Figures

  • Figure 01: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Distribution, by Region, 2017 and 2026
  • Figure 02: Revenue Share, by Drug Type
  • Figure 03: Global Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast, 2016-2026
  • Figure 04: Global Gram-positive Bacterial Infections Market Value Share, by Drug Type (2017)
  • Figure 05: Global Gram-positive Bacterial Infections Market Value Share, by Disease (2017)
  • Figure 06: Global Gram-positive Bacterial Infections Market Value Share, by Route of Administration (2017)
  • Figure 07: Global Gram-positive Bacterial Infections Market Value Share, by Distribution Channel (2017)
  • Figure 08: Global Gram-positive Bacterial Infections Market Value Share, by Region (2017)
  • Figure 09: Number of Patent Applications, 2010-2018 (Based on Priority Year)
  • Figure 10: Patent Application, by Priority Country (2010-2018)
  • Figure 11: Contributions (%), from Key Applications- 2010 to 2018
  • Figure 12: Global Gram-positive Bacterial Infections Market Value Share Analysis, by Drug Type, 2017 and 2026
  • Figure 13: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Antibiotic, 2016?2026
  • Figure 14: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Antifungal, 2016?2026
  • Figure 15: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2016?2026
  • Figure 16: Global Gram-positive Bacterial Infections Market Attractiveness Analysis, by Drug Type
  • Figure 17: Global Gram-positive Bacterial Infections Market Value Share Analysis, by Disease, 2017 and 2026
  • Figure 18: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by MRSA, 2016-2026
  • Figure 19: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Pneumonia, 2016-2026
  • Figure 20: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Sepsis, 2016-2026
  • Figure 21: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Sinusitis, 2016-2026
  • Figure 22: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Cellulitis, 2016-2026
  • Figure 23: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Otitis, 2016-2026
  • Figure 24: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Pharyngitis, 2016-2026
  • Figure 25: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Impetigo, 2016-2026
  • Figure 26: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2016?2026
  • Figure 27: Global Gram-positive Bacterial Infections Market Attractiveness Analysis, by Disease
  • Figure 28: Global Gram-positive Bacterial Infections Market Value Share Analysis, by Route of Administration, 2017 and 2026
  • Figure 29: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Enteral, 2016-2026
  • Figure 30: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Parenteral, 2016-2026
  • Figure 31: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2016?2026
  • Figure 32: Gram-positive Bacterial Infections Market Attractiveness Analysis, by Route of Administration
  • Figure 33: Global Gram-positive Bacterial Infections Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 34: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2016-2026
  • Figure 35: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Drug Stores and Retail Pharmacies, 2016-2026
  • Figure 36: Global Gram-positive Bacterial Infections Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2016?2026
  • Figure 37: Gram-positive Bacterial Infections Market Attractiveness Analysis, by Distribution Channel
  • Figure 38: Global Gram-positive Bacterial Infections Market Value Share, by Region, 2017 and 2026
  • Figure 39: Global Gram-positive Bacterial Infections Market Attractiveness Analysis, by Region, 2018-2026
  • Figure 40: North America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016-2026
  • Figure 41: North America Gram-positive Bacterial Infections Market Value Share, by Country, 2017 and 2026
  • Figure 42: North America Gram-positive Bacterial Infections Market Attractiveness, by Country, 2017-2026
  • Figure 43: North America Gram-positive Bacterial Infections Market Value Share, by Drug Type, 2017 and 2026
  • Figure 44: North America Gram-positive Bacterial Infections Market Attractiveness, by Drug Type, 2017-2026
  • Figure 45: North America Gram-positive Bacterial Infections Market Value Share, by Disease, 2017 and 2026
  • Figure 46: North America Gram-positive Bacterial Infections Market Attractiveness, by Disease, 2017-2026
  • Figure 47: North America Gram-positive Bacterial Infections Market Value Share, by Route of Administration, 2017 and 2026
  • Figure 48: North America Gram-positive Bacterial Infections Market Attractiveness, by Route of Administration, 2017-2026
  • Figure 49: North America Gram-positive Bacterial Infections Market Value Share, by Distribution Channel, 2017 and 2026
  • Figure 50: North America Gram-positive Bacterial Infections Market Attractiveness, by Distribution Channel, 2017-2026
  • Figure 51: Europe Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016-2026
  • Figure 52: Europe Gram-positive Bacterial Infections Market Value Share, by Country/Sub-region, 2017 and 2026
  • Figure 53: Europe Gram-positive Bacterial Infections Market Attractiveness, by Country/Sub-region, 2017-2026
  • Figure 54: Europe Gram-positive Bacterial Infections Market Value Share, by Drug Type, 2017 and 2026
  • Figure 55: Europe Gram-positive Bacterial Infections Market Attractiveness, by Drug Type, 2017-2026
  • Figure 56: Europe Gram-positive Bacterial Infections Market Value Share, by Disease, 2017 and 2026
  • Figure 57: Europe Gram-positive Bacterial Infections Market Attractiveness, by Disease, 2017-2026
  • Figure 58: Europe Gram-positive Bacterial Infections Market Value Share, by Route of Administration, 2017 and 2026
  • Figure 59: Europe Gram-positive Bacterial Infections Market Attractiveness, by Route of Administration, 2017-2026
  • Figure 60: Europe Gram-positive Bacterial Infections Market Value Share, by Distribution Channel, 2017 and 2026
  • Figure 61: Europe Gram-positive Bacterial Infections Market Attractiveness, by Distribution Channel, 2017-2026
  • Figure 62: Asia Pacific Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016-2026
  • Figure 63: Asia Pacific Gram-positive Bacterial Infections Market Value Share, by Country/Sub-region, 2017 and 2026
  • Figure 64: Asia Pacific Gram-positive Bacterial Infections Market Attractiveness, by Country/Sub-region, 2017-2026
  • Figure 65: Asia Pacific Gram-positive Bacterial Infections Market Value Share, by Drug Type, 2017 and 2026
  • Figure 66: Asia Pacific Gram-positive Bacterial Infections Market Attractiveness, by Drug Type, 2017-2026
  • Figure 67: Asia Pacific Gram-positive Bacterial Infections Market Value Share, by Disease, 2017 and 2026
  • Figure 68: Asia Pacific Gram-positive Bacterial Infections Market Attractiveness, by Disease, 2017-2026
  • Figure 69: Asia Pacific Gram-positive Bacterial Infections Market Value Share, by Route of Administration, 2017 and 2026
  • Figure 70: Asia Pacific Gram-positive Bacterial Infections Market Attractiveness, by Route of Administration, 2017-2026
  • Figure 71: Asia Pacific Gram-positive Bacterial Infections Market Value Share, by Distribution Channel, 2017 and 2026
  • Figure 72: Asia Pacific Gram-positive Bacterial Infections Market Attractiveness, by Distribution Channel, 2017-2026
  • Figure 73: Latin America Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016-2026
  • Figure 74: Latin America Gram-positive Bacterial Infections Market Value Share, by Country/Sub-region, 2017 and 2026
  • Figure 75: Latin America Gram-positive Bacterial Infections Market Attractiveness, by Country/Sub-region, 2017-2026
  • Figure 76: Latin America Gram-positive Bacterial Infections Market Value Share, by Drug Type, 2017 and 2026
  • Figure 77: Latin America Gram-positive Bacterial Infections Market Attractiveness, by Drug Type, 2017-2026
  • Figure 78: Latin America Gram-positive Bacterial Infections Market Value Share, by Disease, 2017 and 2026
  • Figure 79: Latin America Gram-positive Bacterial Infections Market Attractiveness, by Disease, 2017-2026
  • Figure 80: Latin America Gram-positive Bacterial Infections Market Value Share, by Route of Administration, 2017 and 2026
  • Figure 81: Latin America Gram-positive Bacterial Infections Market Attractiveness, by Route of Administration, 2017-2026
  • Figure 82: Latin America Gram-positive Bacterial Infections Market Value Share, by Distribution Channel, 2017 and 2026
  • Figure 83: Latin America Gram-positive Bacterial Infections Market Attractiveness, by Distribution Channel, 2017-2026
  • Figure 84: Middle East & Africa Gram-positive Bacterial Infections Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016-2026
  • Figure 85: Middle East & Africa Gram-positive Bacterial Infections Market Value Share, by Country/Sub-region, 2017 and 2026
  • Figure 86: Middle East & Africa Gram-positive Bacterial Infections Market Attractiveness, by Country/Sub-region, 2017-2026
  • Figure 87: Middle East & Africa Gram-positive Bacterial Infections Market Value Share, by Drug Type, 2017 and 2026
  • Figure 88: Middle East & Africa Gram-positive Bacterial Infections Market Attractiveness, by Drug Type, 2017-2026
  • Figure 89: Middle East & Africa Gram-positive Bacterial Infections Market Value Share, by Disease, 2017 and 2026
  • Figure 90: Middle East & Africa Gram-positive Bacterial Infections Market Attractiveness, by Disease, 2017-2026
  • Figure 91: Middle East & Africa Gram-positive Bacterial Infections Market Value Share, by Route of Administration, 2017 and 2026
  • Figure 92: Middle East & Africa Gram-positive Bacterial Infections Market Attractiveness, by Route of Administration, 2017-2026
  • Figure 93: Middle East & Africa Gram-positive Bacterial Infections Market Value Share, by Distribution Channel, 2017 and 2026
  • Figure 94: Middle East & Africa Gram-positive Bacterial Infections Market Attractiveness, by Distribution Channel, 2017-2026
Back to Top